Medexus Pharmaceuticals Inc. (TSX: MDP)

Canada flag Canada · Delayed Price · Currency is CAD
3.250
+0.200 (6.56%)
Dec 24, 2024, 12:59 PM EST
48.40%
Market Cap 80.12M
Revenue (ttm) 141.52M
Net Income (ttm) 3.10M
Shares Out 24.65M
EPS (ttm) 0.12
PE Ratio 27.60
Forward PE 7.69
Dividend n/a
Ex-Dividend Date n/a
Volume 15,179
Open 3.080
Previous Close 3.050
Day's Range 3.060 - 3.250
52-Week Range 1.470 - 3.270
Beta 1.96
Analysts n/a
Price Target n/a
Earnings Date Feb 6, 2025

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical ... [Read more]

Sector Healthcare
CEO Kenneth d'Entremont
Employees 82
Stock Exchange Toronto Stock Exchange
Ticker Symbol MDP
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.